Immunomodulation based on a two-way paradigm with deoxyspergualin alleviates graft-versus-host reaction in small-bowel transplantation in rats

Y. Kimura, Takahito Yagi, H. Iwagaki, K. Watanabe, K. Kai, M. Yamamura, M. Inagaki, S. Tanaka, N. Tanaka

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In this study, we investigated whether or not deoxyspergualin used as donor pretreatment, with and without pretreatment using bone-marrow-cell injection, could alleviate graft-versus-host reaction (GVHR) following small-bowel transplantation in an unidirectional GVHR model with Lewis (LEW)-to-F1 rats. In addition, we studied the effect of deoxyspergualin plus bone-marrow-cell donor pre-operative treatment in combination with recipient post-operative treatment using deoxyspergualin. When the donor was pretreated with bone-marrow cells from recipient rats, the recipient died at 7.2 ± 1.4 days, showing significantly shorter survival compared with the control group. Deoxyspergualin, when employed either alone as recipient post-treatment or as donor pretreatment, both with and without additional pre-treatment with F1 recipient bone-marrow-cell injection, did not result in significant prolongation of recipient survival. The combination of donor pretreatment with deoxyspergualin plus F1 bone-marrow-cell injection followed by post-operative deoxyspergualin administration, however, resulted in significant prolongation in recipient survival compared with control (26.1 ± 1.7 days). In addition, no severe cutaneous lesions on GVHR were seen throughout the observation period. This suggests that donor pretreatment with deoxyspergualin and recipient bone-marrow-cell injection combined with post-operative deoxyspergualin administration can lead to resistance to GVHR after parent-to-F1 small-bowel transplantation.

Original languageEnglish
Pages (from-to)214-221
Number of pages8
JournalJournal of International Medical Research
Volume29
Issue number3
Publication statusPublished - 2001

Fingerprint

Graft vs. host reactions
Transplantation (surgical)
Immunomodulation
Rats
Transplantation
Bone Marrow Cells
Transplants
Bone
Injections
gusperimus
Therapeutics

Keywords

  • Bone-marrow cell
  • Deoxyspergualin
  • Graft-versus-host reaction
  • Small-bowel transplantation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Immunomodulation based on a two-way paradigm with deoxyspergualin alleviates graft-versus-host reaction in small-bowel transplantation in rats. / Kimura, Y.; Yagi, Takahito; Iwagaki, H.; Watanabe, K.; Kai, K.; Yamamura, M.; Inagaki, M.; Tanaka, S.; Tanaka, N.

In: Journal of International Medical Research, Vol. 29, No. 3, 2001, p. 214-221.

Research output: Contribution to journalArticle

Kimura, Y, Yagi, T, Iwagaki, H, Watanabe, K, Kai, K, Yamamura, M, Inagaki, M, Tanaka, S & Tanaka, N 2001, 'Immunomodulation based on a two-way paradigm with deoxyspergualin alleviates graft-versus-host reaction in small-bowel transplantation in rats', Journal of International Medical Research, vol. 29, no. 3, pp. 214-221.
Kimura, Y. ; Yagi, Takahito ; Iwagaki, H. ; Watanabe, K. ; Kai, K. ; Yamamura, M. ; Inagaki, M. ; Tanaka, S. ; Tanaka, N. / Immunomodulation based on a two-way paradigm with deoxyspergualin alleviates graft-versus-host reaction in small-bowel transplantation in rats. In: Journal of International Medical Research. 2001 ; Vol. 29, No. 3. pp. 214-221.
@article{d6e9ff98ab074daea5e7da13e0696172,
title = "Immunomodulation based on a two-way paradigm with deoxyspergualin alleviates graft-versus-host reaction in small-bowel transplantation in rats",
abstract = "In this study, we investigated whether or not deoxyspergualin used as donor pretreatment, with and without pretreatment using bone-marrow-cell injection, could alleviate graft-versus-host reaction (GVHR) following small-bowel transplantation in an unidirectional GVHR model with Lewis (LEW)-to-F1 rats. In addition, we studied the effect of deoxyspergualin plus bone-marrow-cell donor pre-operative treatment in combination with recipient post-operative treatment using deoxyspergualin. When the donor was pretreated with bone-marrow cells from recipient rats, the recipient died at 7.2 ± 1.4 days, showing significantly shorter survival compared with the control group. Deoxyspergualin, when employed either alone as recipient post-treatment or as donor pretreatment, both with and without additional pre-treatment with F1 recipient bone-marrow-cell injection, did not result in significant prolongation of recipient survival. The combination of donor pretreatment with deoxyspergualin plus F1 bone-marrow-cell injection followed by post-operative deoxyspergualin administration, however, resulted in significant prolongation in recipient survival compared with control (26.1 ± 1.7 days). In addition, no severe cutaneous lesions on GVHR were seen throughout the observation period. This suggests that donor pretreatment with deoxyspergualin and recipient bone-marrow-cell injection combined with post-operative deoxyspergualin administration can lead to resistance to GVHR after parent-to-F1 small-bowel transplantation.",
keywords = "Bone-marrow cell, Deoxyspergualin, Graft-versus-host reaction, Small-bowel transplantation",
author = "Y. Kimura and Takahito Yagi and H. Iwagaki and K. Watanabe and K. Kai and M. Yamamura and M. Inagaki and S. Tanaka and N. Tanaka",
year = "2001",
language = "English",
volume = "29",
pages = "214--221",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "3",

}

TY - JOUR

T1 - Immunomodulation based on a two-way paradigm with deoxyspergualin alleviates graft-versus-host reaction in small-bowel transplantation in rats

AU - Kimura, Y.

AU - Yagi, Takahito

AU - Iwagaki, H.

AU - Watanabe, K.

AU - Kai, K.

AU - Yamamura, M.

AU - Inagaki, M.

AU - Tanaka, S.

AU - Tanaka, N.

PY - 2001

Y1 - 2001

N2 - In this study, we investigated whether or not deoxyspergualin used as donor pretreatment, with and without pretreatment using bone-marrow-cell injection, could alleviate graft-versus-host reaction (GVHR) following small-bowel transplantation in an unidirectional GVHR model with Lewis (LEW)-to-F1 rats. In addition, we studied the effect of deoxyspergualin plus bone-marrow-cell donor pre-operative treatment in combination with recipient post-operative treatment using deoxyspergualin. When the donor was pretreated with bone-marrow cells from recipient rats, the recipient died at 7.2 ± 1.4 days, showing significantly shorter survival compared with the control group. Deoxyspergualin, when employed either alone as recipient post-treatment or as donor pretreatment, both with and without additional pre-treatment with F1 recipient bone-marrow-cell injection, did not result in significant prolongation of recipient survival. The combination of donor pretreatment with deoxyspergualin plus F1 bone-marrow-cell injection followed by post-operative deoxyspergualin administration, however, resulted in significant prolongation in recipient survival compared with control (26.1 ± 1.7 days). In addition, no severe cutaneous lesions on GVHR were seen throughout the observation period. This suggests that donor pretreatment with deoxyspergualin and recipient bone-marrow-cell injection combined with post-operative deoxyspergualin administration can lead to resistance to GVHR after parent-to-F1 small-bowel transplantation.

AB - In this study, we investigated whether or not deoxyspergualin used as donor pretreatment, with and without pretreatment using bone-marrow-cell injection, could alleviate graft-versus-host reaction (GVHR) following small-bowel transplantation in an unidirectional GVHR model with Lewis (LEW)-to-F1 rats. In addition, we studied the effect of deoxyspergualin plus bone-marrow-cell donor pre-operative treatment in combination with recipient post-operative treatment using deoxyspergualin. When the donor was pretreated with bone-marrow cells from recipient rats, the recipient died at 7.2 ± 1.4 days, showing significantly shorter survival compared with the control group. Deoxyspergualin, when employed either alone as recipient post-treatment or as donor pretreatment, both with and without additional pre-treatment with F1 recipient bone-marrow-cell injection, did not result in significant prolongation of recipient survival. The combination of donor pretreatment with deoxyspergualin plus F1 bone-marrow-cell injection followed by post-operative deoxyspergualin administration, however, resulted in significant prolongation in recipient survival compared with control (26.1 ± 1.7 days). In addition, no severe cutaneous lesions on GVHR were seen throughout the observation period. This suggests that donor pretreatment with deoxyspergualin and recipient bone-marrow-cell injection combined with post-operative deoxyspergualin administration can lead to resistance to GVHR after parent-to-F1 small-bowel transplantation.

KW - Bone-marrow cell

KW - Deoxyspergualin

KW - Graft-versus-host reaction

KW - Small-bowel transplantation

UR - http://www.scopus.com/inward/record.url?scp=0034939024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034939024&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 214

EP - 221

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 3

ER -